FRESENIUS SE+CO.KGAA O.N.
FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
FRE
|
09/01/2025 16:31:37
|
Chg.
+0.590
|
Volume |
Bid16:41:11 |
Ask16:41:11 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
34.960EUR
|
+1.72%
|
0
Turnover: 0.000 |
35.010Bid Size: 1,150 |
35.030Ask Size: 1,150 |
19.7 bill.EUR |
- |
- |
Business description
Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care.
Management board & Supervisory board
| CEO |
| Michael Sen |
| Management board |
| Sara Hennicken, Pierluigi Antonelli , Robert Möller, Michael Moser |
| Supervisory board |
| Wolfgang Kirsch, Prof. Dr. D. Michael Albrecht, Bernd Behlert , Michael Diekmann , Grit Genster , Frauke Lehmann , Prof. Dr. med. Iris Löw-Friedrich , Susanne Zeidler , Dr. Christoph Zindel , Holger Michel, Harald Steer, Oscar Romero de Paco |
Company data
| Name: |
Fresenius SE & Co. KGaA |
| Address: |
Else-Kröner-Straße 1,D-61352 Bad Homburg |
| Phone: |
+49-6172-608-0 |
| Fax: |
- |
| E-mail: |
pr-fre@fresenius.com
|
| Internet: |
www.fresenius.de |
| Industry: |
Healthcare |
| Sector: |
Medical Products |
| Sub sector: |
Advanced Medical Devices |
| End of financial year: |
31/12 |
| Free Float: |
56.49% |
| IPO date: |
18/12/1986 |
Investor relations
| Name: |
Markus Georgi |
| IR phone: |
+49-6172-608-2485 |
| IR Fax: |
+49-6172-608-2488 |
| IR e-mail: |
ir-fre@fresenius.com
|
Company calendar
|
CW 9 | 26/02/2025
Annual Report
|
|
CW 19 | 07/05/2025
Interim Report 1st Quarter/3 Months
|
|
CW 21 | 23/05/2025
General Shareholder Meeting
|
|
CW 32 | 06/08/2025
Interim Report 2nd Quarter/6 Months
|
|
CW 45 | 05/11/2025
Interim Report 3rd Quarter/9 Months
|